comparemela.com
Home
Live Updates
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy : comparemela.com
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 - - Initial data... | May 18, 2023
Related Keywords
Canada ,
Boston ,
Massachusetts ,
United States ,
Laurence Watts ,
James Mcarthur ,
Gilmartin Group ,
Pepgen Inc ,
Health Canada ,
Head Of Clinical Development At Pepgen ,
Nasdaq ,
Clinical Trial Application ,
Michelle Mellion ,
Clinical Development ,
Drug Safety Monitoring Board ,
Enhanced Delivery Oligonucleotide ,
Private Securities Litigation Reform Act ,
Pepgen Inc Stock Exchange ,
News ,
Information ,
Press Release ,
Hill ,
Ssess ,
Dystrophin ,
Exon ,
Skipping ,
Data ,
End ,
Safety ,
Following ,
Multiple ,
Doses ,
F ,
N ,
Patients ,
Ith ,
Mutations ,
Aamenable ,
O ,
1 ,
Nitial Pepg Us7133171055 ,
comparemela.com © 2020. All Rights Reserved.